Holen Sie sich die Stockscreener-App
2.00
2.91%
-0.06
Avenue Therapeutics Inc Aktie (ATXI) Neueste Nachrichten
Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR
Subaru Corp Leads Third Avenue Value Fund's Strategic Moves in Q4 2024 - Yahoo Finance
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com Australia
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Postoperative Pain Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
SL Green Completes Loan Modification at One Madison Avenue - Yahoo Finance
APLT (Applied Therapeutics) Enterprise Value : $139.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Avenue Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
APLT (Applied Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Canadian North Resources Inc. Announces Appointment Of Henderson Tse To The Board Of Directors - The Manila Times
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Expedia faces threat from tepid growth in 2025, Deutsche Bank says after downgrade - Investing.com
Avenue Therapeutics director Jay Kranzler sells $136 in stock - Investing.com India
Avenue Therapeutics director Jay Kranzler sells $136 in stock By Investing.com - Investing.com UK
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - Business Wire
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - StockTitan
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC - Yahoo Finance
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Forest Avenue Capital Management LP Has $44.92 Million Position in Walmart Inc. (NYSE:WMT) - Defense World
Postoperative acute pain Market Size is Set for Rapid Growth as - openPR
3.26%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):